In this issue:
Murine study links maternal stress during pregnancy to paediatric AD
Flares important for assessment of AD severity and disease prognosis
Lebrikizumab efficacious for AD inadequately controlled with cyclosporine
Low risk of adverse events with topical ruxolitinib: should US boxed warning be reconsidered?
Topical ruxolitinib may be as effective as systemic agents for moderate disease
DAMASK fails to demonstrate efficacy for IRAK4 inhibitor zabedosertib
Blood transcriptome signature predicts efficacy of abrocitinib
Is the effectiveness of upadacitinib reduced in patients who failed prior biologic therapy?
Dupilumab associated with weight gain
Clinical course of disease after dupilumab discontinuation
Please login below to download this issue (PDF)